ANTIDIABETIC TREATMENT AND CANCER PREVALENCE IN DIABETIC PATIENTS
Keywords:
diabetes mellitus, metformin, insulin treatment, cancer, prevalence
Abstract
Background: There can be a possible relationship between diabetes mellitus and cancer development, according to the literature. The aim of the present study was to investigate the relationship between diabetes and prevalence of cancer.
Method: This study consisted of 306 patients with diabetes who referred to Haseki Training and Research Hospital Diabetes outpatient clinic between 2000–2002. Patients were followed up until October 2011 and medical records were evaluated. The prevalence of cancer was investigated retrospectively in these patients. Findings were evaluated statistically.
Results: The prevalence of was cancer was established to be 3.3% in the present study. The relation between the ages and HDL-cholesterol values of patients and cancer prevalence was found to be statistically significant, respectively p 0.024 and 0.037.
Conclusion: Cancer prevalence was found to be higher than that in the normal population. However, the number of cases was low, which may be the reason why results in other studies are not similar. There is agreement that cancer prevalence increases in diabetic patients.
Downloads
Download data is not yet available.
References
1. Otake S, Takeda H, Suzuki Y, Fukui T, Watanabe S, Ishihama K, et al. Association of visceral fat accumulation and plasma adiponectin with colorectal adenoma: Evidence for Participation of Insulin Resistance. Clinical Cancer Research 2005;15;11(10):3642-6.
2. Bugianesi E: Steatosis, the metabolic syndrome, and cancer. Aliment Pharmacol Ther 2005;22: 40-3
3. Nieves DJ, Cnop M, Retzlaff B, Walden CE, Brunzell JD, Knopp RH, et al. The atherogenic lipoprotein profile associated with obesity and insulin resistance is largely attributable to intraabdominal fat. Diabetes 2003;52(1):172-9
4. Kanai H, Tokunaga K, Fujioka S, Yamashita S, Kameda-Takemura KK, et al. Decrease in intra-abdominal visceral fat may reduce blood pressure in obese hypertensive women. Hypertension 1996;27(1):125-9.
5. Kopelman PG. Hormones and obesity. Bailliere’s Clinical Endocrinology and Metabolism 1994;8(3):549-75.
6. Chow WH, BlotWJ, Vaughan TL, Risch HA, Gammon MD, Stanford JL et al. Body mass index and risk of adenocarcinomas of the esophagus and gastric cardia. J Natl Cancer Inst 1998;21;90(2):150-5.
7. Adachi Y, Lee CT, Coffee K, Yamagata N, Ohm JE, Park KH et al. Effects of the genetic blockade of the insulin-like growth factor receptor in human colon cancer cell lines. Gastroenterology 2002;123(4):1191-204.
8. Payer J, Jackuliak P, Nagyová M. Obesity and a risk of carcinoma. Vnitr Lek 2010;56: 1082-7.
9. Tilg H, Moschen AR. Adipocytokines: mediators linking adipose tissue, inflammation, and immunity. Nat Rev Immunol 2006;6:772–83.
10. Voulgaris Z. Plasma adiponectin concentrations in relation to endometrial cancer: A case-control study in Greece. The Journal of Clinical Endocrinology & Metabolism 2003; 88(3):993-7.
11. Kern PA, Di Gregorio GB, Lu T, Rassouli N, Ranganathan G. Adiponectin expression from human adipose tissue relation to obesity, insulin resistance, and tumor necrosis factor expression. American Diabetes Association Diabetes2003;52(7):177985
12. Wei EK, Giovannuchi E. Fuchs CS, Willett WC, Mantzoros CS. Low plasma adiponectin levels and risk of colorectal cancer in men: A prospective study. Journal of the National Cancer Institute 2005;9:22. 13. Stattin P, Lukanova A, Biessy C, Soderberg S, Palmqvist R, Kaaks R, et al. Obesity and colon cancer: does leptin provide a link? Int J Cancer 2004;109(1):149-52.
14. Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 2005, 55:74-108
15. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global Cancer Statistics. CA Cancer J Clin 2011; 61:69–90
16. Giovanucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA, Pollak M, Regensteiner JG, Yee D, Diabetes and Cancer: a consensus statement of the American Diabetes Association Diabetes Care 2010; 33: S:213-216
17. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B, American Diabetes Association, European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for Study of Diabetes. Diabetes Care 2009; 32: 193-203
18. Bibliographic details: Yin M, Zhou J, Gorak EJ, Quddus F. Metformin is associated with survival benefit in cancer patients with concurrent type 2 diabetes: a systematic review and metaanalysis. Oncologist 2013; 18(12): 1248-1255.
19. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD, Metformin and reduced risk of cancer in diabetic patients. BMJ 2005;330:1304-1305
20. Zi F, Zi H, Li Y, He J, Shi Q, Cai Z. Metformin and cancer: An existing drug for cancer prevention and therapy. Oncology Letters 2018;15(1):683-690. doi:10.3892/ol.2017.7412.
21. Landman GW, Kleefstra N, van Hateren KJ, Groenier KH, Gans RO, Bilo HJ. Metformin associated with lower cancer mortality in type2 diabetes. Diabetes Care 2010;33(2):322-6. doi: 10.2337/dc09-1380.
22. Kim HJ, Lee S, Chun KH, et al. Metformin reduces the risk of cancer in patients with type 2 diabetes: An analysis based on the Korean National Diabetes Program Cohort. Yong. TY, ed. Medicine 2018;97(8):e0036. doi:10.1097/MD.0000000000010036.
23. Bibliographic details: He S, Tang YH, Zhao G, Yang X, Wang D, Zhang Y. Pioglitazone prescription increases the risk of bladder cancer in patients with type 2 diabetes: an updated metaanalysis. Tumor Biology 2014; 35(3):2095-2102. [PubMed]
24. Bowker SL, Majumdar SR, Veugelers P, Johnson JA. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 2006; 29:254-258
25. Currie CJ, Poole CD, Gale EA. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 2009;52:1766-1777
26. Jonasson JM, Ljung R, Talback M, Haglund B, Gudbjornsdottir S, Steineck G. Insulin glargine use and short-term incidence of malignancies-a populationbased follow-up study in Sweden. Diabetologia 2009; 52:1745-1754
27. Rosenstock J, Fonseca V, McGill JB, Riddle M, Halle JP, Hramiak I, Johnston P, Davis M. Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomized, open-label study. Diabetologia 2009; 52:1971-1973.
28. Lim S, September KG, He W, et al. Electronic Medical Record Cancer Incidence over Six Years Comparing New Users of Glargine with New Users of NPH Insulin. PLoS One 2014;9(10):e109433. doi:10.1371/journal.pone.0109433.
29. Mori Y, Ko E, Furrer R, et al. Effects of insulin and analogs on carcinogeninduced mammary tumors in high-fatfed rats. Endocrine Connections 2018; 7(5): 739-748. doi:10.1530/EC-17-0358.
2. Bugianesi E: Steatosis, the metabolic syndrome, and cancer. Aliment Pharmacol Ther 2005;22: 40-3
3. Nieves DJ, Cnop M, Retzlaff B, Walden CE, Brunzell JD, Knopp RH, et al. The atherogenic lipoprotein profile associated with obesity and insulin resistance is largely attributable to intraabdominal fat. Diabetes 2003;52(1):172-9
4. Kanai H, Tokunaga K, Fujioka S, Yamashita S, Kameda-Takemura KK, et al. Decrease in intra-abdominal visceral fat may reduce blood pressure in obese hypertensive women. Hypertension 1996;27(1):125-9.
5. Kopelman PG. Hormones and obesity. Bailliere’s Clinical Endocrinology and Metabolism 1994;8(3):549-75.
6. Chow WH, BlotWJ, Vaughan TL, Risch HA, Gammon MD, Stanford JL et al. Body mass index and risk of adenocarcinomas of the esophagus and gastric cardia. J Natl Cancer Inst 1998;21;90(2):150-5.
7. Adachi Y, Lee CT, Coffee K, Yamagata N, Ohm JE, Park KH et al. Effects of the genetic blockade of the insulin-like growth factor receptor in human colon cancer cell lines. Gastroenterology 2002;123(4):1191-204.
8. Payer J, Jackuliak P, Nagyová M. Obesity and a risk of carcinoma. Vnitr Lek 2010;56: 1082-7.
9. Tilg H, Moschen AR. Adipocytokines: mediators linking adipose tissue, inflammation, and immunity. Nat Rev Immunol 2006;6:772–83.
10. Voulgaris Z. Plasma adiponectin concentrations in relation to endometrial cancer: A case-control study in Greece. The Journal of Clinical Endocrinology & Metabolism 2003; 88(3):993-7.
11. Kern PA, Di Gregorio GB, Lu T, Rassouli N, Ranganathan G. Adiponectin expression from human adipose tissue relation to obesity, insulin resistance, and tumor necrosis factor expression. American Diabetes Association Diabetes2003;52(7):177985
12. Wei EK, Giovannuchi E. Fuchs CS, Willett WC, Mantzoros CS. Low plasma adiponectin levels and risk of colorectal cancer in men: A prospective study. Journal of the National Cancer Institute 2005;9:22. 13. Stattin P, Lukanova A, Biessy C, Soderberg S, Palmqvist R, Kaaks R, et al. Obesity and colon cancer: does leptin provide a link? Int J Cancer 2004;109(1):149-52.
14. Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 2005, 55:74-108
15. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global Cancer Statistics. CA Cancer J Clin 2011; 61:69–90
16. Giovanucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA, Pollak M, Regensteiner JG, Yee D, Diabetes and Cancer: a consensus statement of the American Diabetes Association Diabetes Care 2010; 33: S:213-216
17. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B, American Diabetes Association, European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for Study of Diabetes. Diabetes Care 2009; 32: 193-203
18. Bibliographic details: Yin M, Zhou J, Gorak EJ, Quddus F. Metformin is associated with survival benefit in cancer patients with concurrent type 2 diabetes: a systematic review and metaanalysis. Oncologist 2013; 18(12): 1248-1255.
19. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD, Metformin and reduced risk of cancer in diabetic patients. BMJ 2005;330:1304-1305
20. Zi F, Zi H, Li Y, He J, Shi Q, Cai Z. Metformin and cancer: An existing drug for cancer prevention and therapy. Oncology Letters 2018;15(1):683-690. doi:10.3892/ol.2017.7412.
21. Landman GW, Kleefstra N, van Hateren KJ, Groenier KH, Gans RO, Bilo HJ. Metformin associated with lower cancer mortality in type2 diabetes. Diabetes Care 2010;33(2):322-6. doi: 10.2337/dc09-1380.
22. Kim HJ, Lee S, Chun KH, et al. Metformin reduces the risk of cancer in patients with type 2 diabetes: An analysis based on the Korean National Diabetes Program Cohort. Yong. TY, ed. Medicine 2018;97(8):e0036. doi:10.1097/MD.0000000000010036.
23. Bibliographic details: He S, Tang YH, Zhao G, Yang X, Wang D, Zhang Y. Pioglitazone prescription increases the risk of bladder cancer in patients with type 2 diabetes: an updated metaanalysis. Tumor Biology 2014; 35(3):2095-2102. [PubMed]
24. Bowker SL, Majumdar SR, Veugelers P, Johnson JA. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 2006; 29:254-258
25. Currie CJ, Poole CD, Gale EA. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 2009;52:1766-1777
26. Jonasson JM, Ljung R, Talback M, Haglund B, Gudbjornsdottir S, Steineck G. Insulin glargine use and short-term incidence of malignancies-a populationbased follow-up study in Sweden. Diabetologia 2009; 52:1745-1754
27. Rosenstock J, Fonseca V, McGill JB, Riddle M, Halle JP, Hramiak I, Johnston P, Davis M. Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomized, open-label study. Diabetologia 2009; 52:1971-1973.
28. Lim S, September KG, He W, et al. Electronic Medical Record Cancer Incidence over Six Years Comparing New Users of Glargine with New Users of NPH Insulin. PLoS One 2014;9(10):e109433. doi:10.1371/journal.pone.0109433.
29. Mori Y, Ko E, Furrer R, et al. Effects of insulin and analogs on carcinogeninduced mammary tumors in high-fatfed rats. Endocrine Connections 2018; 7(5): 739-748. doi:10.1530/EC-17-0358.
How to Cite
1.
Mehmet Yamak, İbrahim Halil Boyacı, Süleyman Ahbab, Emre Hoca, Hayriye Esra Ataoğlu. ANTIDIABETIC TREATMENT AND CANCER PREVALENCE IN DIABETIC PATIENTS. Med. res. chronicles [Internet]. 2018Oct.31 [cited 2024Apr.27];5(5):351-6. Available from: https://medrech.com/index.php/medrech/article/view/324
Section
Original Research Article
